≡

C-Met (MET)

[Edit]

HGFR; RCCP2; Hepatocyte Growth Factor Receptor; Met Proto-Oncogene; Mesenchymal-Epithelial Transition Factor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; Tyrosine-protein kinase M

C-Met (MET)
CCC C186
HGNC 7029
MGI 96969
PubMed 11750879
RGD 3082
UniProt P08581
Wiki HGFR

MET (mesenchymal-epithelial transition factor) is a proto-oncogene that encodes a protein MET, also known as c-Met or hepatocyte growth factor receptor (HGFR). The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.
MET is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the MET receptor. MET is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPC186Hu01 Recombinant C-Met (MET) Positive Control; Immunogen; SDS-PAGE; WB.
RPC186Hu02 Recombinant C-Met (MET) Positive Control; Immunogen; SDS-PAGE; WB.
APC186Hu01 Active C-Met (MET) Cell culture; Activity Assays.
Antibodies PAC186Hu01 Polyclonal Antibody to C-Met (MET) WB; IHC
MAC186Hu22 Monoclonal Antibody to C-Met (MET) WB; IHC; ICC; IP.
Assay Kits SEC186Hu ELISA Kit for C-Met (MET) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPC186Mu01 Recombinant C-Met (MET) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies n/a Monoclonal Antibody to C-Met (MET) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to C-Met (MET) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for C-Met (MET) CLIA Kit Customized Service Offer
n/a ELISA Kit for C-Met (MET) ELISA Kit Customized Service Offer

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant C-Met (MET) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to C-Met (MET) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to C-Met (MET) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for C-Met (MET) CLIA Kit Customized Service Offer
n/a ELISA Kit for C-Met (MET) ELISA Kit Customized Service Offer
  1. "Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors."Proc. Natl. Acad. Sci. U.S.A. 84:6379-6383(1987) [PubMed] [Europe PMC] [Abstract]
  2. "Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis."Arthritis Res. Ther. 10:R73-R73(2008) [PubMed] [Europe PMC] [Abstract]
  3. "The DNA sequence of human chromosome 7." Nature 424:157-164(2003) [PubMed] [Europe PMC] [Abstract]
  4. "Human chromosome 7: DNA sequence and biology." Science 300:767-772(2003) [PubMed] [Europe PMC] [Abstract]
  5. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  6. "Primary structure of the met protein tyrosine kinase domain."Oncogene 1:229-233(1987) [PubMed] [Europe PMC] [Abstract]
  7. "A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes."Oncogene 8:3403-3410(1993) [PubMed] [Europe PMC] [Abstract]
  8. "The human met oncogene is related to the tyrosine kinase oncogenes."Nature 318:385-388(1985) [PubMed] [Europe PMC] [Abstract]
  9. "The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors."Int. J. Cancer 49:323-328(1991) [PubMed] [Europe PMC] [Abstract]
  10. "The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase."J. Biol. Chem. 266:22087-22090(1991) [PubMed] [Europe PMC] [Abstract]
  11. "Expression of the Met/HGF receptor in normal and neoplastic human tissues."Oncogene 6:1997-2003(1991) [PubMed] [Europe PMC] [Abstract]
  12. "Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product."Science 251:802-804(1991) [PubMed] [Europe PMC] [Abstract]
  13. "Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase."J. Biol. Chem. 266:19558-19564(1991) [PubMed] [Europe PMC] [Abstract]
  14. "A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family."Cell 77:261-271(1994) [PubMed] [Europe PMC] [Abstract]
  15. "Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium."J. Clin. Invest. 93:2056-2065(1994) [PubMed] [Europe PMC] [Abstract]
  16. "Induction of epithelial tubules by growth factor HGF depends on the STAT pathway."Nature 391:285-288(1998) [PubMed] [Europe PMC] [Abstract]
  17. "Grb10, a positive, stimulatory signaling adapter in platelet-derived growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis."Mol. Cell. Biol. 19:6217-6228(1999) [PubMed] [Europe PMC] [Abstract]
  18. "Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM."J. Biol. Chem. 277:36216-36222(2002) [PubMed] [Europe PMC] [Abstract]
  19. "c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination."J. Immunol. 169:3793-3800(2002) [PubMed] [Europe PMC] [Abstract]
  20. "The semaphorin 4D receptor controls invasive growth by coupling with Met."Nat. Cell Biol. 4:720-724(2002) [PubMed] [Europe PMC] [Abstract]
  21. "Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1."J. Biol. Chem. 278:5728-5735(2003) [PubMed] [Europe PMC] [Abstract]
  22. "A novel MET-interacting protein shares high sequence similarity with RanBPM, but fails to stimulate MET-induced Ras/Erk signaling."Biochem. Biophys. Res. Commun. 313:320-326(2004) [PubMed] [Europe PMC] [Abstract]
  23. "MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met."Mol. Cell. Biol. 24:7456-7468(2004) [PubMed] [Europe PMC] [Abstract]
  24. "The SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading."Oncogene 24:3436-3447(2005) [PubMed] [Europe PMC] [Abstract]
  25. "Invasive growth: a MET-driven genetic programme for cancer and stem cells."Nat. Rev. Cancer 6:637-645(2006) [PubMed] [Europe PMC] [Abstract]
  26. "Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase."J. Biol. Chem. 283:34374-34383(2008) [PubMed] [Europe PMC] [Abstract]
  27. "Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle."Mol. Cell 31:438-448(2008) [PubMed] [Europe PMC] [Abstract]
  28. "A quantitative atlas of mitotic phosphorylation."Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed] [Europe PMC] [Abstract]
  29. "Identification of N-glycosylation sites on secreted proteins of human hepatocellular carcinoma cells with a complementary proteomics approach."J. Proteome Res. 8:662-672(2009) [PubMed] [Europe PMC] [Abstract]
  30. "Large-scale proteomics analysis of the human kinome."Mol. Cell. Proteomics 8:1751-1764(2009) [PubMed] [Europe PMC] [Abstract]
  31. "The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas."Biochim. Biophys. Acta 1806:208-219(2010) [PubMed] [Europe PMC] [Abstract]
  32. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]
  33. "Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET."J. Biol. Chem. 286:32762-32774(2011) [PubMed] [Europe PMC] [Abstract]
  34. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]
  35. "Dimer formation through domain swapping in the crystal structure of the Grb2-SH2-Ac-pYVNV complex."Biochemistry 39:13376-13382(2000) [PubMed] [Europe PMC] [Abstract]
  36. "Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a."Proc. Natl. Acad. Sci. U.S.A. 100:12654-12659(2003) [PubMed] [Europe PMC] [Abstract]
  37. "Insights into function of PSI domains from structure of the Met receptor PSI domain."Biochem. Biophys. Res. Commun. 321:234-240(2004) [PubMed] [Europe PMC] [Abstract]
  38. "Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor."EMBO J. 23:2325-2335(2004) [PubMed] [Europe PMC] [Abstract]
  39. "Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB."Cell 130:235-246(2007) [PubMed] [Europe PMC] [Abstract]
  40. "Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas." Nat. Genet. 16:68-73(1997) [PubMed] [Europe PMC] [Abstract]
  41. "Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene."Cancer Res. 58:1719-1722(1998) [PubMed] [Europe PMC] [Abstract]
  42. "Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype."Am. J. Pathol. 155:517-526(1999) [PubMed] [Europe PMC] [Abstract]
  43. "Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas."Cancer Res. 59:307-310(1999) [PubMed] [Europe PMC] [Abstract]
  44. "Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family."Int. J. Cancer 82:640-643(1999) [PubMed] [Europe PMC] [Abstract]
  45. "Novel mutations of the MET proto-oncogene in papillary renal carcinomas."Oncogene 18:2343-2350(1999) [PubMed] [Europe PMC] [Abstract]
  46. "A novel germ line juxtamembrane Met mutation in human gastric cancer."Oncogene 19:4947-4953(2000) [PubMed] [Europe PMC] [Abstract]
  47. "A novel germline mutation in the MET extracellular domain in a Korean patient with the diffuse type of familial gastric cancer."J. Med. Genet. 40:E97-E97(2003) [PubMed] [Europe PMC] [Abstract]
  48. "The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway."J. Biol. Chem. 280:16393-16401(2005) [PubMed] [Europe PMC] [Abstract]
  49. "A genetic variant that disrupts MET transcription is associated with autism."Proc. Natl. Acad. Sci. U.S.A. 103:16834-16839(2006) [PubMed] [Europe PMC] [Abstract]
  50. "Patterns of somatic mutation in human cancer genomes." Nature 446:153-158(2007) [PubMed] [Europe PMC] [Abstract]
  51. "MET mutations in cancers of unknown primary origin (CUPs)."Hum. Mutat. 32:44-50(2011) [PubMed] [Europe PMC] [Abstract]